New Aspects of Genetic Basis, Classification and Treatment of Osteogenesis Imperfecta: Literature Review
https://doi.org/10.15690/pf.v12i5.1461
Abstract
Osteogenesis imperfecta is characterized by increased congenital brittleness of bones with a broad spectrum of clinical manifestations — from perinatal/lethal form and severe bone deformities to the mildest forms. In most cases, the disease is caused by autosomaldominant mutation in the collagen 1 gene. At present, the approach to patients with osteogenesis imperfecta is multidisciplinary. Bisphosphonate drug therapy is conducted to reduce the incidence of fractures in the process of treatment, which also involves active rehabilitation and surgical correction of bone deformities. A more profound understanding of pathogenesis of osteogenesis imperfecta may lead to a development of new and effective therapeutic approaches capable of improving functional outcomes in patients.
About the Authors
G. T. Yakhyayeva
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
L. S. Namazova-Baranova
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Pirogov Russian National Medical Research University, Moscow, Russian Federation
Russian Federation
Russian Federation
T. V. Margieva
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
References
1. Ekman O. J. Dissertatio medica descriptionem et casus aliquot osteomalaciае sistens. Upsaliае. J Edman. 1788.
2. Steiner R. D., Adsit J., Basel D. COL1A1/2-Related Osteogenesis Imperfecta. Gene Reviews. Seattle: University of Washington. 1993.
3. SillenceD.O., SennA., DanksD.M. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr; 16 (2): 101–116.
4. Martin E., Shapiro J. R. Osteogenesis imperfecta: Epidemiology and pathophysiology. Current Osteoporosis Reports. 2007 Sept; 5 (Issue 3): 91–97.
5. VanDijkF.S., SillenceD.O. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. Part A. Am J Med Genet. 2014; 164A: 1470–1481.
6. Chu M. L., Williams C. J., Pepe G., Hirsch J. L., Prockop D. J., Ramirez F. Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta. Nature. 1983 Jul 7–13; 304 (5921): 78–80.
7. Wallis G. A., Sykes B., Byers P. H., Mathew C. G., Viljoen D., Beighton P. Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible. J Med Genet. 1993 Jun; 30 (6): 492–496.
8. Cheung M. S., Azouz E. M., Glorieux F. H., Rauch F. Hyperplastic callus formation in osteogenesis imperfecta type V: follow-up of three generations over ten years. Skeletal Radiology. 2008 May; 37 (Issue 5): 465–467.
9. Glorieux F. H., Rauch F., Plotkin H., Ward L., Travers R., Roughley P., Lalic L., Glorieux D. F., Fassier F., Bishop N. J. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000 Sep; 15 (9): 1650–8.
10. Rauch F., Glorieux F. H. Osteogenesis imperfecta. Lancet. 2004 Apr 24; 363 (9418): 1377–85.
11. Glorieux F. H., Ward L. M., Rauch F., Lalic L., Roughley P. J., Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. Journal of Bone and Mineral Research. 2002 Jan; 10.1359/jbmr.2002.17.1.30.
12. Ward L. M., Rauch F., Travers R., Chabot G., Azouz E. M., Lalic L., Roughley P. J., Glorieux F. H. Osteogenesis imperfect type VII: an autosomal recessive form of brittle bone disease. Bone. 2002 Jul; 31 (1): 12–8.
13. Barnes A. M., Chang W., Morello R., Cabral W. A., Weis M., Eyre D. R., Leikin S., Makareeva E., Kuznetsova N., Uveges T. E., Ashok A., Flor A. W., Mulvihill J. J., Wilson P. L., Sundaram U. T., Lee B., MariniJ.C. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med. 2006 Dec 28; 355 (26): 2757–64.
14. Cabral W. A., Chang W., Barnes A. M., Weis M., Scott M. A., Leikin S., Makareeva E., Kuznetsova N. V., Rosenbaum K. N., Tifft C. J., Bulas D. I., Kozma C., Smith P. A., Eyre D. R., Marini J. C. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet. 2007 Mar; 39 (3): 359–65. Epub 2007 Feb 4.
15. Van Dijk F. S., Nesbitt I. M., Zwikstra E. H., Nikkels P. G. J., Piersma S. R., Fratantoni S. A., Jimenez C. R., Huizer M., Morsman A. C., Cobben J. M., van Roij M. H. H., Elting M. W., Verbeke J. I. M.L., Wijnaendts L. C. D., Shaw N. J., Hogler W., McKeown C., Sistermans E. A., Dalton A., Meijers-Heijboer H., Pals G. PPIB Mutations Cause Severe Osteogenesis Imperfecta. Am J Hum Genet. 2009; 85: 521–527.
16. Cho T.J., Lee K.E., Lee S.K., Song S.J., Kim K.J., Jeon D., Lee G., Kim H.N., Lee H.R., Eom H.H., Lee Z.H., Kim O.H., Park W.Y., Park S. S., Ikegawa S., Yoo W. J., Choi I. H., Kim J. W. A single recurrent mutation in the 5’-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012 Aug 10; 91 (2): 343–8. Doi: 10.1016/j.ajhg.2012.06.005. Epub 2012 Aug 2.
17. Semler O., Garbes L., Keupp K., Swan D., Zimmermann K., Becker J., Iden S., Wirth B., Eysel P., Koerner F., Schoenau E., Bohlander S. K., Wollnik B., Netzer C. A mutation in the 5’-UTR of IFITM5 creates an in-frame start codon and causes autosomaldominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet. 2012 Aug 10; 91 (2): 349–57. Doi: 10.1016/ j.ajhg.2012.06.011. Epub 2012 Aug 2.
18. Kasaai B., Gaumond M.-H., Moffatt P. PMC3650367 Regulation of the Bone-restricted IFITM-like (Bril) Gene Transcription by Sp and Gli Family Members and CpG Methylation. J Biol Chem. 2013 May 10; 288 (19): 13278–13294.
19. Hanagata N., Li X., Morita H., Takemura T., Li J., Minowa T. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J Bone Miner Metab. 2011 May; 29 (3): 279–90. Doi: 10.1007/s00774-010-0221-0. Epub 2010 Sep 14.
20. van Dijk F. S., Cobben J. M., Kariminejad A. A., Maugeri P. G. J., Nikkels R. R., van Pals R. G. Osteogenesis imperfecta: a review with clinical examples. Mol Syndromol. 2011; 2: 1–20.
21. Warman M. L., Cormier-Daire V., Hall C., Krakow D., Lachman R., LeMerrer M., Mortier G., Mundlos S., Nishimura G., Rimoin D. L., Robertson S., Savarirayan R., Sillence D., Spranger J., Unger S., Zabel B., Superti-Furga A. Nosology and Classification of Genetic Skeletal Disorders: 2010 Revision. Am J Med Genet. 2011 May; 155 (5): 943–968. Published online 2011 Mar 15. Doi: 10.1002/ajmg. a.33909.
22. van Dijk F. S., Zillikens M. C., Micha D., Riessland M., Marcelis C. L., de Die-Smulders C. E., Milbradt J., Franken A. A., Harsevoort A. J., Lichtenbelt K. D., Pruijs H. E., Rubio-Gozalbo M. E., Zwertbroek R., Moutaouakil Y., Egthuijsen J., Hammerschmidt M., Bijman R., Semeins C. M., Bakker A. D., Everts V., Klein-Nulend J., Campos-Obando N., Hofman A., Meerman G. J., Verkerk A. J., Uitterlinden A. G., Maugeri A., Sistermans E. A., Waisfisz Q., Meijers-Heijboer H., Wirth B., Simon M. E., Pals G. PLS3 mutations in X-linked osteoporosis with fractures. N Engl J Med. 2013 Oct 17; 369 (16): 1529–36. Doi: 10.1056/NEJMoa1308223. Epub 2013 Oct 2.
23. Venturi G., Tedeschi E., Mottes M., Valli M., Camilot M., Viglio S., Antoniazzi F., Tato L. Clin Genet. 2006 Aug; 70 (2): 131–9.
24. Kuurila K., Kaitila I., Johansson R., Grenman R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann Otol Rhinol Laryngol. 2002 Oct; 111 (10): 939–46.
25. Sillence D. Osteogenesis imperfecta: an expanding panorama of variants. Am J Med Genet. 1984 Feb; 17 (2):407–23.
26. Sinikumpu JJ, Ojaniemi M, Lehenkari P, Serlo W. Severe osteogenesis imperfecta Type-III and its challenging treatment in newborn and preschool children. A systematic review. Injury. 2015 Aug; 46 (8): 1440–6. doi: 10.1016/j.injury.2015.04.021.
27. Mercedes Rios-Rodenas, Joaquin de Nova, Maria-Pilar GutierrezDiez, Gonzalo Feijoo, Maria-Rosa Mourelle, Mario Garcilazo, and Ricardo Ortega-Aranegui. A cephalometric method to diagnosis the craniovertebral junction abnormalities in osteogenesis imperfecta patients. J Clin Exp Dent. 2015 Feb; 7 (1): e153–e158. doi: 10.4317/jced.52126
28. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000 Sep; 15 (9): 1650–8.
29. Tae-Joon Cho, Kyung-Eun Lee, Sook-Kyung Lee, Su Jeong Song, Kyung Jin Kim, Daehyun Jeon, Gene Lee, Ha-Neui Kim, Hye Ran Lee, Hye-Hyun Eom, Zang Hee Lee, Ok-Hwa Kim, Woong-Yang Park, Sung Sup Park, Shiro Ikegawa, Won Joon Yoo, In Ho Choi, and Jung-Wook Kim. A Single Recurrent Mutation in the 5’-UTR of IFITM5 Causes Osteogenesis Imperfecta Type V. Am J Hum Genet. 2012 Aug 10; 91 (2): 343–348. doi: 10.1016/j.ajhg.2012.06.005
30. Devogelaer J.P., Malghem J., Maldague B., Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a children suffering from osteogenesis imperfecta. Skeletal Radiol. 1987; 16 (5): 360–363. [PubMed].
31. Monti E., Mottes M., Fraschini P., Brunelli P. C., Forlino A., Venturi G., Doro F., Perlini S., Cavarzere P., Antoniazzi F. Ther Clin Risk Manag. 2010; 6: 367–381. Published online 2010 Sept. 7. PMCID: PMC2940745.
32. Drake M. T., MD, PhD, Clarke B. L., MD, Khosla S., MD. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc. 2008 Sep; 83 (9): 1032–1045. Doi: 10.4065/83.9.1032.
33. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998; 19: 80–100. [PubMed].
34. RussellR.G. Bisphosphonates: from bench to bedside. Ann N. Y. Acad Sci. 2006; 1068: 367–401. [PubMed].
35. Luckman S. P., Hughes D. E., Coxon F. P. et al. Nitrohen-containing bisphosphonates inhibit mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteinsm including RAS. J Bone Miner Res. 1998; 13: 581–9.
36. Bergstrom J. D. et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000; 373: 231–41.
37. Glorieux F. H., Bishop N. J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339: 947–952. [PubMed].
38. Andiran N., Alikasifoglu A., Gonc N., Ozon A., Kandemir N., Yordam N. J Pediatr Endocrinol Metab. 2008 Jan; 21 (1): 63–72.
39. Gatti D., Rossini M., Viapiana O., Idolazzi L., Adami S. Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag. 2013; 9: 139–147. Doi: 10.2147/TCRM.S35788.
40. Semler O., Beccard R., Palmisano D., Demant A., Fricke O., Schoenau E., Koerber F. Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta. Horm Res Paediatr. 2011; 76 (5): 321–7. Doi: 10.1159/000331128. Epub 2011 Sep 27.
41. Gatti D., Antoniazzi F., Prizzi R., Braga V., Rossini M., Tato L., Viapiana O., Adami S. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research. 2005 May; 20 (Issue 5): 758–763.
42. Antoniazzi F., Zamboni G., Lauriola S., Donadi L., Adami S., Tato L. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr. 2006 Aug; 149 (2): 174–179.
43. Barros E. R., Saraiva G. L., de Oliveira T. P., Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfect. J Pediatr Endocrinol Metab. 2012; 25 (5–6): 485–91.
44. Vuorimies I., Toiviainen-Salo S., Hero M., Makitie O. Zoledronic acid treatment in children with osteogenesis imperfect. Horm Res Paediatr. 2011; 75 (5): 346–53. Doi: 10.1159/000323368. Epub 2011 Feb 2.
45. Bishop N., Adami S., Faisal S., Arundel P., Burren C. P., Devogelaer J.-P., Hangartner T., Hosszu E., Lane J. M., Lorenc R., Makitie O., Munns C. F., Paredes A. et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebocontrolled trial. Lancet. 2013 Oct; 382 (Issue 9902): 1424–1432. Doi:10.1016/S0140-6736(13)61091-0.
46. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014 Jul 23;7: CD005088. doi: 10.1002/14651858. CD005088.pub3
47. Никитинская О. А., Торопцова Н. В. Деносумаб — первый генно-инженерный препарат для лечения остеопороза. Современная ревматология. 2012; 3. URL: http://cyberleninka.ru/ article/n/denosumab-pervyy-genno-inzhenernyy-preparat-dlyalecheniya-osteoporoza (дата обращения: 07.09.2014).
48. Semler O., Netzer C., Hoyer-Kuhn H., Becker J., Eysel P., Schoenau E. First use of the RANKL antibody denosumab in osteogenesis imperfect type VI. J Musculoskelet Neuronal Interact. 2012 Sep; 12 (3): 183–8.
49. Eisman J. A., Bone H. G., Hosking D. J., McClung M. R., Reid I. R., Rizzoli R. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res. 2011; 26 (2): 242.
50. Bone H. G., McClung M. R., Roux C., Recker R. R., Eisman J. A., VerbruggenN. et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010; 25 (5): 937–47.
51. Antoniazzi F., Bertoldo F., Mottes M., Valli M., Sirpresi S., Zamboni G., Valentini R., Tato L. Growth hormone treatment in osteogenesis imperfect with quantitative defect of type I collagen synthesis. J Pediatr. 1996 Sep; 129 (3): 432–9.
52. Antoniazzi F., Monti E., Venturi G., Franceschi R., Doro F., Gatti D., Zamboni G., Tato L. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol. 2010 Sep; 163 (3): 479–87. Doi: 10.1530/EJE-10-0208. Epub 2010 Jun 30.
53. Orwoll E. S., Sandesh C. S. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta Published February 3, 2014 Citation Information. J Clin Invest. 2014; 124 (2): 491–498. Doi: 10.1172/JCI71101.
54. Vahle J., Sato M., Long G., Young J., Francis P., Engelhardt J. et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30: 312–321. [PubMed].
55. Balemans W., Ebeling M., Patel N., van Hul E., Olson P., Dioszegi M., LaczaC.,WuytsW.,vandenEndeJ.,WillemsP.,BuenoM.,RamosF.J., Tacconi P., Dikkers F. G., Stratakis C., Lindpaintner K., Vickery B., Foernzler D., van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10 (5): 537–543. Doi: 10.1093/hmg/10.5.537.
56. Costa A. G., Bilezikian J. P., Lewiecki E. M. Update on romosozumab: a humanized monoclonal antibody to sclerostin. 2014 May; 14 (5): 697–707. Doi:10.1517/14712598.2014.895808.
57. ClarkeB.L. Anti-sclerostin antibodies: utility in treatment of osteoporosis. 2014 Jul; 78 (3): 199–204. Doi: 10.1016/j.maturitas. 2014.04.016. Epub 2014 May 2.
Review
For citations:
Yakhyayeva G.T., Namazova-Baranova L.S., Margieva T.V. New Aspects of Genetic Basis, Classification and Treatment of Osteogenesis Imperfecta: Literature Review. Pediatric pharmacology. 2015;12(5):579-588. (In Russ.) https://doi.org/10.15690/pf.v12i5.1461
Views:
2936
Email this article 